Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 9/20 | 0.55 |
| ▸ | ERBB2 | P04626 | 7/20 | 0.55 |
| ▸ | LCK | P06239 | 1/20 | 0.55 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.55 |
| ▸ | STK4 | Q13043 | 4/20 | 0.53 |
| ▸ | STK3 | Q13188 | 4/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.51 |
| ▸ | AURKA | O14965 | 1/20 | 0.50 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.50 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.48 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9719826 | 0.86 | EGFR (0.59) | EGFRERBB2LCKP2RX4GRM4 | |
| SCHEMBL9719862 | 0.83 | ERBB2 (0.74) | EGFRERBB2LCKP2RX4STK3 | |
| SCHEMBL31084744 | 0.83 | ERBB2 (0.74) | EGFRERBB2LCKP2RX4STK3 | |
| SCHEMBL30053083 | 0.81 | GRM4 (0.60) | EGFRERBB2LCKP2RX4GRM4 | |
| SCHEMBL31084742 | 0.80 | EGFR (0.70) | EGFRERBB2LCKP2RX4GRM4 | |
| SCHEMBL11893942 | 0.78 | EGFR (0.58) | EGFRERBB2LCKP2RX4GRM4 | |
| SCHEMBL4619419 | 0.77 | EGFR (0.70) | EGFRERBB2ERBB4 | |
| SCHEMBL27751267 | 0.77 | ERBB2 (0.58) | EGFRERBB2LCKP2RX4STK4 | |
| SCHEMBL31084741 | 0.77 | EGFR (0.59) | EGFRERBB2LCKP2RX4GRM4 | |
| SCHEMBL23859935 | 0.76 | ERBB2 (0.57) | EGFRERBB2LCKP2RX4STK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023174449-A1 | METHOD FOR PREPARING N-(3-CHLORO-4-(2-PYRIDYLMETHOXY)PHENYL)-2-CYANOACETAMIDE | 安庆朗坤药业有限公司 | 2023-09-21 | — | — | WO | claimed |
| CN-114736154-B | Process for preparing N- (3-chloro-4- (2-pyridylmethoxy) phenyl) -2-cyanoacetamide | 安庆朗坤药业有限公司 | 2023-07-21 | — | — | CN | claimed |
| CN-114736154-A | Preparation method of N- (3-chloro-4- (2-pyridylmethoxy) phenyl) -2-cyanoacetamide | 安庆朗坤药业有限公司 | 2022-07-12 | — | — | CN | claimed |
| CN-110818619-B | Synthetic method of N- (3-chloro-4- (2-pyridylmethoxy) phenyl) -2-cyanoacetamide | 山东铂源药业有限公司 | 2021-03-02 | — | — | CN | claimed |
| CN-110818619-A | Synthetic method of N- (3-chloro-4- (2-pyridylmethoxy) phenyl) -2-cyanoacetamide | 山东铂源药业有限公司 | 2020-02-21 | — | — | CN | claimed |
| US-20230303523-A1 | METHOD FOR PREPARING PYROTINIB | SUZHOU FUSHILAI PHARMACEUTICAL CO., LTD (CN) | 2023-09-28 | — | — | US | disclosed |
| WO-2023174449-A1 | METHOD FOR PREPARING N-(3-CHLORO-4-(2-PYRIDYLMETHOXY)PHENYL)-2-CYANOACETAMIDE | 安庆朗坤药业有限公司 | 2023-09-21 | — | — | WO | disclosed |
| WO-2023174449-A1 | METHOD FOR PREPARING N-(3-CHLORO-4-(2-PYRIDYLMETHOXY)PHENYL)-2-CYANOACETAMIDE | 安庆朗坤药业有限公司 | 2023-09-21 | — | — | WO | disclosed |
| WO-2023174449-A1 | METHOD FOR PREPARING N-(3-CHLORO-4-(2-PYRIDYLMETHOXY)PHENYL)-2-CYANOACETAMIDE | 安庆朗坤药业有限公司 | 2023-09-21 | — | — | WO | disclosed |
| CN-114736154-B | Process for preparing N- (3-chloro-4- (2-pyridylmethoxy) phenyl) -2-cyanoacetamide | 安庆朗坤药业有限公司 | 2023-07-21 | — | — | CN | disclosed |
| CN-114736154-B | Process for preparing N- (3-chloro-4- (2-pyridylmethoxy) phenyl) -2-cyanoacetamide | 安庆朗坤药业有限公司 | 2023-07-21 | — | — | CN | disclosed |
| CN-114736154-B | Process for preparing N- (3-chloro-4- (2-pyridylmethoxy) phenyl) -2-cyanoacetamide | 安庆朗坤药业有限公司 | 2023-07-21 | — | — | CN | disclosed |
| CN-110818619-B | Synthetic method of N- (3-chloro-4- (2-pyridylmethoxy) phenyl) -2-cyanoacetamide | 山东铂源药业有限公司 | 2021-03-02 | — | — | CN | disclosed |
| CN-110818619-B | Synthetic method of N- (3-chloro-4- (2-pyridylmethoxy) phenyl) -2-cyanoacetamide | 山东铂源药业有限公司 | 2021-03-02 | — | — | CN | disclosed |
| CN-110818619-A | Synthetic method of N- (3-chloro-4- (2-pyridylmethoxy) phenyl) -2-cyanoacetamide | 山东铂源药业有限公司 | 2020-02-21 | — | — | CN | disclosed |
| CN-110818619-A | Synthetic method of N- (3-chloro-4- (2-pyridylmethoxy) phenyl) -2-cyanoacetamide | 山东铂源药业有限公司 | 2020-02-21 | — | — | CN | disclosed |
| CN-110818619-A | Synthetic method of N- (3-chloro-4- (2-pyridylmethoxy) phenyl) -2-cyanoacetamide | 山东铂源药业有限公司 | 2020-02-21 | — | — | CN | disclosed |
| EP-1883621-A2 | METHODS OF PREPARING 3-CYANO-QUINOLINES AND INTERMEDIATES MADE THEREBY | Wyeth (US) | 2008-02-06 | — | — | EP | disclosed |
| US-20060270669-A1 | Method of preparing 3-cyano-quinolines and intermediates made thereby | WYETH | 2006-11-30 | — | — | US | disclosed |
| WO-2006127205-A2 | METHODS OF PREPARING 3-CYANO-QUINOLINES AND INTERMEDIATES MADE THEREBY | WYETH (US) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270669-A1 | Method of preparing 3-cyano-quinolines and intermediates made thereby | CNP, PPP4C, PTMS | EGFR 3894/4885ERBB2 2020/4885LCK 1082/4885 |
| US-20230303523-A1 | METHOD FOR PREPARING PYROTINIB | JAK2, SRMS, JAK1 | EGFR 934/4885ERBB2 672/4885LCK 1943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.